Form 4: Cigna Director George Kurian Acquires Phantom Stock Units Through Deferred Compensation Plan

Director George Kurian acquired 88.8099 phantom stock units of Cigna through a deferred compensation plan, equivalent to common stock shares.

Summary

• George Kurian, a director at Cigna Group, acquired 88.8099 phantom stock units on November 29, 2024.
• These units were acquired through the company's Deferred Compensation Plan for Directors.
• The phantom stock units represent a deferral of a portion of Kurian's cash retainer into a hypothetical stock fund.
• Each phantom stock unit is economically equivalent to one share of Cigna's common stock.
• The units will be settled in cash, not in actual shares.
• The transaction also includes 4.5836 phantom stock units acquired through a dividend reinvestment feature of the plan.
• Following the transaction, Kurian now holds 1,263.0537 phantom stock units.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally neutral to positive. It indicates the director's participation in the company's long-term incentive plans.

Positives

• The acquisition of phantom stock units demonstrates the director's participation in the company's long-term incentive plans.
• The dividend reinvestment feature further increases the director's stake in the company.

Future Outlook

The phantom stock units will be settled in cash at a future date, as per the terms of the Deferred Compensation Plan.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It reflects a director's participation in the company's compensation plans.

Comparison to Industry Standards

• Deferred compensation plans are a common practice for directors and executives in publicly traded companies, including those in the healthcare sector like UnitedHealth Group and Humana.
• The use of phantom stock units is a typical method to align the interests of directors with the long-term performance of the company, similar to practices seen at other large corporations such as CVS Health and Anthem.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement, ensuring transparency in insider dealings, which is consistent across all publicly listed companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Cigna, phantom stock units, deferred compensation, director, insider trading, Form 4, executive compensation